Benzonatate

As a commonly used peripheral antitussive drug in clinical practice, benzonatate is a non-addictive antitussive belonging to the tetracaine derivative category, and its mechanism of action is significantly different from that of central antitussive drugs: it exerts an antitussive effect by inhibiting pulmonary stretch receptors and sensory nerve endings and blocking the afferent impulse of the cough reflex. Meanwhile, it does not inhibit the respiratory center, and can reduce the airway resistance of patients with asthma. Clinically, it is mainly used for irritating dry cough and paroxysmal cough caused by acute bronchitis, bronchial asthma, pneumonia, lung cancer and other conditions. It can also be used for cough prevention before examinations such as bronchoscopy and laryngoscopy, and is suitable for patients who are not suitable for central antitussive drugs, especially the elderly and people with underlying respiratory diseases.

The global benzonatate market size was approximately USD 210 million in 2023, and is expected to grow steadily at a compound annual growth rate of 3.2% from 2024 to 2030. The growth momentum mainly comes from the rising prevalence of chronic respiratory diseases and the increasing clinical demand for non-addictive antitussive drugs. Currently, original research products account for nearly 60% of the market share, and generic drugs are mainly produced and supplied by Indian and Chinese enterprises. Relevant dosage forms have not yet been included in domestic centralized procurement, so there is sufficient space for generic drug substitution.

The original research enterprise of benzonatate is Pfizer Inc., and its original research brand name is Tessalon Perles. The compound patent for the US market expired in 1962. The main dosage form of the original research product is soft capsule, with specifications including 50mg, 100mg and 200mg, which has been included in the FDA Reference Listed Drug Catalog. As of June 2025, there is no benzonatate API that has been registered with the CDE (A status registration number) in China. Only a few domestic enterprises have submitted clinical registration applications for relevant preparations, and no domestic benzonatate preparation products have been approved for marketing yet. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for benzonatate API. Most of the products are in regular stock. For in-stock orders placed before 16:00, the delivery can be made on the same day. The products meet the compliance requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, and can provide stable and reliable support for impurity control in drug R&D, quality research and production links.